# Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

> **NCT02947867** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Gene Signal SAS** · enrollment: 333 (estimated)

## Conditions studied

- Ischaemic Central Retinal Vein Occlusion
- Neovascular Glaucoma

## Interventions

- **DRUG:** aganirsen

## Key facts

- **NCT ID:** NCT02947867
- **Lead sponsor:** Gene Signal SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 333 (ESTIMATED)
- **Last updated:** 2016-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947867, "Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02947867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*